“…RESULTS: Of the 13,162 patients in the study, the median duration of recovery was 8 days (interquartile range IQR, 6–10 d), 41.31% recovered within 7 days, and 94.83% recovered within 14 days. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Results: (1) The statistic analysis confirmed that there were seven independent predictors of malignant lesions, including thickened endometrium (premenopause ≥ 18.5 mm, postmenopause ≥ 15.5 mm), non-uniform endometrial echogenicity (heterogeneous with irregular cysts), endometrial midline appearance (not defined), the endometrial–myometrial junction (interrupted or not defined), intracavitary fluid (ground glass or “mixed” echogenicity), color score (3~4 points) and vascular pattern (focal origin multiple vessels or multifocal origin multiple vessels). (2) In traditional ultrasound GI-RADS (U-T-GI-RADS), if category 4a was taken as the cut-off value of benign and malignant, the diagnostic sensitivity, specificity, PPV, NPV and diagnostic accuracy were 97.2%, 65.2%, 44.0%, 98.8% and 72.2%, respectively, and the area under the ROC curve (AUC) was 0.812. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Dentre os sintomáticos, os sintomas mais citados foram cefaleia 229 (52,8%), tosse 198 (45,7%), perda de paladar/olfato 180 (41,6%), rinorreia 180 (41,6%) e febre 141 (32,6%). …”
Enlace del recurso
Enlace del recurso

“…RESULTADOS: Conforme os dois períodos analisados (pandemia e pós pandemia) observou-se: aumento de 89,6% no comparecimento as unidades de doação citadas (12.422 para 23.586); de 98,3% do sexo masculino (6.364 para 12.625); 81% do sexo feminino (6.057 para 10.961); 61,6% quanto ao tipo de doação espontânea (4.501 para 7.278) e de 171% de doação de reposição (5.253 para 14.240); 153,7% quanto ao tipo de doador primeira vez (4.716 para 11.967) e 133,8% de doador esporádico (2.567 para 6.002). Por outro lado, houve uma queda de 9,3% quanto tipo de doador de repetição (5.138 para 5.617); 26,9% (165 para 130) quanto a faixa etária da procura pela doação em candidatos menores de 18 anos e de 17,7% (1.904 para 1.617) em candidatos de 50 a 59 anos. …”
Enlace del recurso
Enlace del recurso

“…As médias de idade foram de 49,8 anos para participantes com doença leve a moderada e de 61,3 anos para o grupo de doença grave a crítica. …”
Enlace del recurso
Enlace del recurso

“…During a median observation period of 10 [95% CI: 5 – 19] months, the HeartLogic index crossed the alert-threshold value 73 times (0.72 alerts/patient-year) in 39 patients. 8 HF hospitalizations and 2 emergency room admissions occurred in 9 patients (0.10 events/patient-year) during HeartLogic IN alert state. …”
Enlace del recurso
Enlace del recurso

“…Further analysis suggested that the expression of TGFBI to correlate positively with the expression of identified and validated proteins such as GFPT2, FLNA, G6PD, ITGAV, ITGA1 and ITGA2; and with the infiltration of CD8(+) T cells, macrophages, neutrophils, and dendritic cells in the TME. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: Median duration of luspatercept exposure for NTD and TD patients was 910 days (range, 40–1850) and 433 days (range, 21–1790), respectively. Seventeen of 31 (54.8%) NTD patients achieved a mean hemoglobin increase of ⩾1.5 g/dl and 19 of 32 (59.4%) TD patients achieved ⩾50% reduction in RBC transfusion burden, during any continuous 12-week period. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Au cours des 3 mois post-vaccination, 81 % des patients immunocompétents obtenaient une réponse humorale à des taux protecteurs, contre 56 % des patients avec immunosuppression (IS) médicamenteuse (rituximab, corticoïdes ≥ 10 mg/j, MMF, cyclophosphamide, azathioprine). Après 4 à 8 mois, ce taux diminuait dans les 2 groupes (59 % et 38 %, respectivement). …”
Enlace del recurso
Enlace del recurso

“…La base française de PV comporte 8 cas de NE. Un cas survenu chez une patiente asiatique avec HLA favorisant était plutôt lié à la lamotrigine d’après le calcul du score ALDEN (6 pour lamotrigine et 2 pour le vaccin), 4 cas étaient probablement des erreurs diagnostiques ou non médicamenteux (1 érythème polymorphe, 1 NE post-mycoplasme, 1 éruption morbiliforme et 1 surdosage en méthotrexate) et pour 1 cas, les données descriptives étaient manquantes. …”
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, sneezing, cough, malaise, sore throat, and fever (usually < 37.8 ºC). Whilst the common cold is generally not harmful, it is a cause of economic burden due to school and work absenteeism. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Cumulative incidence curves and multivariable Cox regression analyses were used to determine the association of pre-HCT CMV antibody epitopes scores with CMV reactivation (any, >150 IU/mL, >500 IU/mL) in the first 8 weeks post-HCT. RESULTS: 170 CMV D-R+ HCT recipients were tested a median of 26 days (range 7-37 days) prior to HCT and had a median of 37 CMV antibody epitopes (IQR 29-50 epitopes, range 14-77 epitopes). …”
Enlace del recurso
Enlace del recurso

“…Adjusted rVE of 3 doses compared to 2 doses of mRNA-1273 against SARS-CoV-2 infection, COVID-19 hospitalization, and COVID-19 hospital death were 55.0% (95% CI: 50.8–58.9%), 83.0% (75.4–88.3%), and 87.1% (30.6–97.6%), respectively (Table 1). …”
Enlace del recurso
Enlace del recurso

“…Successful EORTC-MSGERC overall response(2) (OR, complete or partial based on clinical + radiologic + mycologic improvement) was 47%/42% in IA (Day 42/D84, n = 53), 53%/53% (L. prolificans, n=17), 55%/36% (Scedosporium, n=11), and 50%/50% (other moulds, n=8). Stable response at D42/D84 predicted extended therapy responses, especially in HAU-IFI of brain and bone (Figure). …”
Enlace del recurso
Enlace del recurso

“…Of these, 2 participants experienced clinical progression: 1 participant infected with the Mu variant (500 mg IV) carried the characteristic R346K substitution at BL; 1 participant infected with the Delta variant (500 mg IM) had P337L and E340K substitutions detected at Day 3 and P337L was enriched at Day 8. The predominant TE epitope substitutions included P337L and E340A/K/V, which confer reduced susceptibility to sotrovimab in vitro. …”
Enlace del recurso
Enlace del recurso

“…RÉSULTATS: Au total, 216 patients (dont 121 patients ayant des facteurs de risque cardiovasculaire) ont reçu un traitement prophylactique par anticorps monoclonaux (Evusheld), pour les indications suivantes : 110 patients transplantés d’organe, 95 patients traités par anti-CD20, 2 patients traités par chimiothérapie, 8 patients ayant d’autres facteurs d’immunodépression et 1 contre-indication au vaccin. …”
Enlace del recurso
Enlace del recurso

“…La pratique d’APS a globalement diminué pendant le confinement (34,4 % versus 49,0 % pour une pratique < 2 h/semaine et 32,1 % versus 26,8 % pour une pratique > 4 h/semaine). Le score COMI était très significativement impacté (p < 0,0001) par l’aggravation de la douleur, le mauvais vécu du confinement, le manque d’espace et la faible pratique d’APS pendant le confinement. …”
Enlace del recurso
Enlace del recurso

“…Compared with ACEI/ARB, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among patients with HF (RR 1.85, 95% CI 1.12–3.06, p = 0.02) and HFpEF (RR 3.59, 95% CI 1.51–8.55, p = 0.004). Compared with placebo, ACEI/ARB treatment did significantly reduce the risk of new-onset DM among all patients (RR 0.85, 95% CI 0.77–0.93, p = 0.0007) and patients with not all-HF (defined as part of the study population having HF at baseline) (RR 0.87, 95% CI 0.82–0.93, p<0.0001) and HFpEF (RR 0.60, 95% CI 0.44–0.83, p = 0.002), diabetes complications among patients with non-HF (/not all-DM) (RR 0.87, 95% CI 0.76–0.99, p = 0.04), and subsequent diabetes treatment among patients with new-onset DM (RR 0.70, 95% CI 0.58–0.84, p = 0.0002) and significantly increased the risk of hypoglycaemia among patients with not all-DM (RR 2.06, 95% CI 1.172–3.61, p = 0.01). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…During a median follow-up of 3 (IQR 1.2–4.8) years, the adjusted cumulative five-year mortality was 36% in the invasive and 55% in the non-invasive group (hazard ratio 0.68, 95% confidence interval 0.55–0.84). …”
Enlace del recurso
Enlace del recurso

“…This first prototype received marks between 7.0 and 8.0 out of 10 on attractiveness, user‐friendliness, safety, functionality and affordability. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso